Quotidian Hemodialysis and Inflammation Associated With Chronic Kidney Disease

Hamlett, Leslie; Haragsim, Lukas

doi:10.1053/j.ackd.2007.03.006

Cited by 7 publications

(4 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Won et al ( 17 ) found that IL-6 was a strong predictor of ESA hyporesponsiveness and an independent risk factor for resistance to ESA in hemodialysis patients without iron deficiency. Hamlett and Haragsim ( 19 ) reported that more frequent dialysis may have a beneficial effect on the inflammatory process that occurs in ESRD. More frequent (i.e., daily nocturnal) dialysis decreased plasma IL-6 levels and exogenous EPO requirements, and direct associations were found between EPO requirements, CRP (R=0.62, P=0.001) and IL-6 (R=0.57, P=0.002) levels according to a study by Yuen et al.…”

Section: Discussionmentioning

confidence: 99%

The impact of short daily hemodialysis on anemia and the quality of life in Chinese patients

Jiang

Ren

Song

et al. 2013

Braz J Med Biol Res

View full text Add to dashboard Cite

Anemia is a frequent complication in hemodialysis patients. Compared to conventional hemodialysis (CHD), short daily hemodialysis (sDHD) has been reported to be effective in many countries except China. The aim of the present study was to determine whether sDHD could improve anemia and quality of life (QOL) for Chinese outpatients with end-stage renal disease. Twenty-seven patients (16 males/11 females) were converted from CHD to sDHD. All laboratory values were measured before conversion (baseline), at 3 months after conversion (sDHD1), and at 6 months after conversion (sDHD2). The patient's QOL was evaluated at baseline and 6 months after conversion using the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). Hemoglobin concentration increased significantly from 107.4±7.9 g/L at baseline to 114.4±6.8 g/L (P<0.05) at sDHD1, and 118.3±8.4 g/L (P<0.001) at sDHD2 (Student paired t-test). However, the dose requirement for erythropoietin decreased from 6847.8±1057.3 U/week at baseline to 5869.6±1094.6 U/week (P<0.05) at sDHD2. Weekly stdKt/V increased significantly from 2.05±0.13 at baseline to 2.73±0.20 (P<0.001) at sDHD1, and 2.84±0.26 (P<0.001) at sDHD2. C-reactive protein decreased from baseline to sDHD1 and sDHD2, but without statistically significant differences. Physical and mental health survey scores increased in the 6 months following conversion to sDHD. sDHD may increase hemoglobin levels, decrease exogenous erythropoietin dose requirements, and improve QOL in Chinese hemodialysis patients compared to CHD. A possible mechanism for improvement of clinical outcomes may be optimized management of uremia associated with the higher efficiency of sDHD.

show abstract

Section: Discussionmentioning

confidence: 99%

The impact of short daily hemodialysis on anemia and the quality of life in Chinese patients

Jiang

Ren

Song

et al. 2013

Braz J Med Biol Res

View full text Add to dashboard Cite

show abstract

“…Sebagaimana dalam penelitian (Hamlett & Haragsim, 2007) menjelaskan bahwa Frekuensi dialisis yang rutin akan berefek pada proses inflamasi pada pasien gagal ginjal. Semakin sering dialisis akan menurunkan kadar IL-6 plasma dan kebutuhan eritropoietin eksogen.…”

Section: A Gambaran Kadar Hemoglobin Sebelum Dan Setelah Terapi Hemod...unclassified

Analisa Perubahan Kadar Hemoglobin Pada Pasien Gagal Ginjal Kronik (GGK) yang Menjalani Hemodialisa di Rumah Sakit Annisa Cikarang

Mislina

Purwaningsih

Melani

2022

cerdika

View full text Add to dashboard Cite

Latar Belakang: Gagal ginjal kronis (GGK) didefinisikan sebagai kerusakan ginjal yang terjadi lebih dari 3 bulan, berupa kelainan struktural atau fungsional dengan atau tanpa penurunan laju filtrasi glomerulus (LFG). Hemodialisis rutin dilakukan sebagai terapi pengganti fungsi ginjal pada penderita gagal ginjal. Anemia sering ditemukan pada pasien GGK dan dapat menyebabkan penurunan kualitas hidup. Tujuan: Tujuan dilakukannya penelitian ini adalah untuk mengetahui kadar hemoglobin sebelum dan sesudah hemodialisa pada pasien gagal ginjal kronis di Rumah Sakit Annisa Cikarang. Metode: Penelitian ini menggunakan metode penelitian analitik observasional dengan menggunakan data sekunder dan teknik Total Sampling. Sampel yang didapatkan berdasarkan kriteria inklusi dan ekslusi pada penelitian ini berjumlah 30 pasien. Data diambil dan dicatat dari rekam medis pasien GGK di RS Annisa Cikarang periode Juni – Juli 2021. Hasil: Rata-rata kadar hemoglobin pada pasien GGK sebelum diberikan terapi hemodialisis mengalami penurunan yaitu sebesar 8,480mg/dL. Rata-rata kadar hemoglobin setelah diberikan terapi hemodialisis mengalami peningkatan dari sebelum diberikan terapi hemodialisis yaitu 8,857 mg/dL. Terdapat perubahan kadar hemoglobin pada pasien GGK setelah diberikan terapi hemodialysis, dengan nilai P = 0,037 < 0,05. Kesimpulan: Berdasarkan hasil penelitian bahwa menunjukkan bahwa kadar hemoglobin pada pasien GGK sangat rendah dan dibawah batas normal kadar hemoglobin, meskipun terdapat peningkatan kadar hemoglobin setelah diberi terapi hemodialisis namun nilai tersebut masih dibawah batas normal kadar hemoglobin, nilai p lebih rendah dari nilai alpha (batas kemaknaan) dengan demikian H0 gagal diterima yang berarti terdapat perbedaan kadar hemoglobin pada pasien GGK sebelum dan sesudah diberikan terapi hemodialisis.

show abstract

“…Moreover, a better clearance of other uremic compounds was observed: of phosphorus [48,74,80,81,82], urea [47,48,73,74,77,82], homocysteine [83] and advanced glycation endproducts (AGEs, explained in detail below) [84]. Another beneficial aspect could be reduced inflammation as proven by lower levels of the inflammatory markers IL-6, TNF-α and CRP in SDHD patients compared to standard HD [81,85,86]. …”

Section: Influence Of Different Dialysis Therapies On Genomic Damamentioning

confidence: 99%

Genomic Damage in Endstage Renal Disease—Contribution of Uremic Toxins

Schupp

Heidland

Stopper

2010

Toxins

View full text Add to dashboard Cite

Patients with end-stage renal disease (ESRD), whether on conservative, peritoneal or hemodialysis therapy, have elevated genomic damage in peripheral blood lymphocytes and an increased cancer incidence, especially of the kidney. The damage is possibly due to accumulation of uremic toxins like advanced glycation endproducts or homocysteine. However, other endogenous substances with genotoxic properties, which are increased in ESRD, could be involved, such as the blood pressure regulating hormones angiotensin II and aldosterone or the inflammatory cytokine TNF-α. This review provides an overview of genomic damage observed in ESRD patients, focuses on possible underlying causes and shows modulations of the damage by modern dialysis strategies and vitamin supplementation.

show abstract

Quotidian Hemodialysis and Inflammation Associated With Chronic Kidney Disease

Cited by 7 publications

References 72 publications

The impact of short daily hemodialysis on anemia and the quality of life in Chinese patients

The impact of short daily hemodialysis on anemia and the quality of life in Chinese patients

Analisa Perubahan Kadar Hemoglobin Pada Pasien Gagal Ginjal Kronik (GGK) yang Menjalani Hemodialisa di Rumah Sakit Annisa Cikarang

Genomic Damage in Endstage Renal Disease—Contribution of Uremic Toxins

Contact Info

Product

Resources

About